[Late recurrence of stomach cancer in a patient treated with a H2 receptor antagonist].
We report a case where a patient developed recurrence of an adenocarcinoma of the stomach ten years after primary surgery. Besides the late recurrence, the case is interesting as the patient participated in a trial investigating the effect of cimetidine on survival after gastric cancer and received cimetidine for two years after surgery. Considering the well documented anti-tumour and immunomodulating effects of histamine type-2 receptor antagonists, it might be interesting to examine the effect on survival after surgery for gastric cancer in patients receiving prolonged treatment with such an antagonist.
Overgaard
H
H
Organkirurgisk afdeling, Sundby Hospital, København.
Timshel
S
S
D000230:Adenocarcinoma / Q000401:mortality / Q000601:surgery*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002927:Cimetidine / Q000627:therapeutic use*; D006635:Histamine H2 Antagonists / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local; D011182:Postoperative Care; D013274:Stomach Neoplasms / Q000401:mortality / Q000601:surgery*; D013997:Time Factors
D000970:Antineoplastic Agents; D006635:Histamine H2 Antagonists; D002927:Cimetidine
Sent recidiv af cancer ventriculi hos en patient i H2-receptorantagonistbehandling.